Semaglutide activates GLP-1 receptors in your brain and gut, triggering appetite suppression and improved blood sugar controlbut weight loss speed varies significantly between individuals
GHK-Cu is the copper-bound form, used for stability and efficacy
These compounds are particularly concerning due to their widespread distribution and continuous low-level exposure patterns
However, current evidence does not support this concern in practice
This creates an intriguing possibility: GLP-1 therapy might address not just the weight management challenges of Hashimoto's, but also contribute to improving the gut dysfunction that drives the autoimmune process itself
Exenatide has been used against LNCaP, PC3, and DU145 cell lines and showed some significant effect on PCa tumor progression [78, 92]